Essentially the most significant class of antidepressants marketed recently is the selective serotonin reuptake inhibitors (SSRIs). The six SSRIs sold in the usa are citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft). The chief uses for the SSRIs include unipolar and bipolar major depression and every one of the panic attacks. However, controlled trials also support the by using SSRIs within the remedy for other psychiatric disorders including dysthymia, premenstrual dysphoria, bulimia nervosa, obesity, borderline personality disorder, alcoholism, body pain, and migraine headache.
On the list of SSRIs, there are more similarities than differences. Although all SSRI drugs have the same the mechanism of action, each SSRI features a slightly different pharmacological and pharmacokinetic characteristics. This contributes to differences on the list of SSRIs throughout their half-lives, clinical activity, side effects, and drug interactions. There are differences between SSRIs that would be clinically significant.
The earliest drug within the SSRI class was Prozac (Fluoxetine), which hit the united states of america market in 1987. Prozac was FDA approved on December 29, 1987. It is manufactured by Eli Lilly and Company.
Zoloft (Sertraline hydrochloride) was your second SSRI ahead to market in america, it also was approved because of the FDA on December 30, 1991. Zoloft is manufactured by Pfizer Inc.
Paxil (Paroxetine hydrochloride) was the third SSRI to return to market in th usa and was approved from the FDA on December 29, 1992. Paxil is manufactured by GlaxoSmithKline.
Luvox (Fluvoxamine maleate) was the next SSRI FDA approved on December 05, 1994. However, currently its marketing status is "Discontinued".
Celexa (Citalopram hydrobromide) was approved by way of the FDA on July 17, 1998. Celexa is manufactured by Forest Pharmaceuticals, Inc.
Lexapro (Escitalopram oxalate) is the newest and most selective of your SSRIs approved because of the FDA on August 14, 2002. Lexapro is manufactured by Forest Pharmaceuticals, Inc. Lexapro is known as a cleaner, improved edition of Celexa.
Mechanism of impact
The brain communicates with itself utilizing special chemicals called neurotransmitters, for example serotonin and norepinephrine. Neurotransmitters carry signals from a place nerve cell to a new. Low quantities of serotonin and norepinephrine haven t been known to cause depression nonetheless it widely thought that elevation of such chemicals is associated with improvement in mood in depressed people.
All SSRIs possess the same general mechanism of action. SSRIs seem to relieve indicators of depression by blocking the reabsorption (reuptake) of serotonin by certain nerve cells in the brain. This leaves more serotonin available, which enhances neurotransmission (sending of nerve impulses) and improves mood. Sooner or later, the levels of natural serotonin will rise again, and then in some instances the SSRI might be reduced and withdrawn.
Approved indications and makes use of
SSRIs are actually primarily utilized for handling depression but have been studied for some indications not from depression.
Celexa (Citalopram) is indicated for the remedy for:
depression
Lexapro (Escitalopram) is indicated of the remedy for:
major depressive disorder
generalized depression (GAD)
Paxil (Paroxetine) is indicated for treatment of:
major a depressive condition
obsessive compulsive disorder (OCD)
panic disorder
sad (social anxiety disorder)
generalized depression
posttraumatic stress disorder (PTSD)
Prozac (Fluoxetine) is indicated for your remedy for:
major a depressive condition
obsessive-compulsive disorder
moderate to severe bulimia nervosa
panic disorder
in January 2003, Prozac was approved because of the FDA of the treatment of depression and OCD in children and adolescents who are 7 to 17 years more matured.
Zoloft (Sertraline) is indicated of the remedy for:
major a depressive condition
obsessive-compulsive disorder
panic disorder
posttraumatic stress disorder
premenstrual dysphoric disorder (PMDD) in grown-ups (newest indication)
social anxiety disorder
Performance
Clinical trials comparing an SSRI with another SSRI show that drugs in this class are equally efficacious. Each SSRI produces approximately a 60% overall response rate (ie, a minimum of a 50% lowering of symptoms because of treatment).
Unwanted symptoms & unwanted effects
While SSRIs never appear to can be found in overall tolerability, the reported incidences of specific adverse effects vary. Uncomfortable side effects that patients experience are generally mild to moderate and don t require dose reductions or discontinuation. SSRIs possess the following uncomfortable side effects:
Nausea. By far the most coomon symptom accociated with by using SSRIs is nausea. Paroxetine and sertraline are actually linked to a bit more cases of nausea.
Sexual dysfunction. Depression itself may cause impotence and all SSRIs are actually associated with impotence during therapy in men and women. There might be lesser detrimental effect on sexual function by fluoxetine compared to other agents. Citalopram is connected with lack of libido. Paroxetine tends to increase the risk for highest rate of ed.
Anticholinergic effects. Paroxetine causes a higher rate of anticholinergic effects, similar to dry mouth, constipation, and cognitive disruption, when compared with other SSRIs. These effects could be particularly difficult to tolerate for elderly or concomitantly medically ill patients.
Weight. The SSRIs vary throughout their effect on the weight. Sertraline is often connected with a quantity of weight loss inside the acute phase of treatment, whereas paroxetine could cause weight gain after long-term treatment. Fluoxetine has the most potent appetite-suppressing effects throughout shorter term and produces a greater degree of weight loss than paroxetine, sertraline, citalopram, or escitalopram.
Diarrhea. Sertraline and fluoxetine are usually more frequently associated with diarrhea, paroxetine consists of a lower incidence.
Anxiety, agitation, insomnia. Fluoxetine continues to be involved with highest rate of tension and agitation. Escitalopram and paroxatine are more unlikely that to cause insomnia than fluoxetine and sertraline.
Lack of saliva. Citalopram and paroxetine will probably cause sandpaper throat than escitalopram and fluoxetine.
Drowsiness, fatigue. Paroxetine has been involved with highest rate of drowsiness, somnolence compared to other SSRIs.
Headache. Sertraline and fluoxetine are related to greater level of headache.
Regularly, antidepressants might be associated with worsening indicators of depression or suicidal thoughts or behavior, particularly early in treatment or if you improve dosage. Be sure to confer with your doctor about any changes in the symptoms. It is necessary to have more careful monitoring at the beginning of treatment or at the change in treatment, you even may require to halt the medication if your symptoms worsen.
Pharmacokinetics
A few of the key differences among SSRIs are due to differences with their pharmacokinetic properties. The one pharmacokinetic parameters shared by all of the SSRIs is because are relatively slowly, but completely, absorbed from the gut. They differ with regard with their protein binding, metabolism, half-lives, if they have linear or nonlinear pharmacokinetics, if they have active metabolites.
Half-life
The half-life of your drug is the duration needed to achieve steady-state plasma concentrations (i.e., to metabolize half the dose and lower blood concentrations by 50%). Half-life can be used to estimate what amount of time it takes clear a drug coming from the body after treatment is discontinued.
Fluoxetine is special for it's long half-life along with the long half-life of their active metabolite norfluoxetine. Fluoxetine features a half-life of 4-6 days and your active metabolite, norfluoxetine, consists of a half-life of 4-16 days. As compared, citalopram, escitalopram, paroxetine, and sertraline have shorter half-lives in the varieties of 20-35 hours, and steady-state concentrations (and therapeutic effect) are reached much more rapidly. The long half-life of fluoxetine may blunt the effects of missed doses or treatment discontinuation and also makes it better to discontinue than any one of the other SSRIs. On the other hand, fluoxetine requires a much longer washout period than the other SSRIs (several weeks), particularly when switching to monoamine oxidase inhibitors (MAOIs) or TCA.
Antidepressants with relatively short half-lives are desirable for individuals with multiple comorbidities and splendid, multiple-drug regimens mainly because they encourage once-daily dosing. Short half-life enables physicians to modify much quicker and safely to an alternative antidepressant if treatment fails or if unfavorable drug reactions occur.
Linear and nonlinear pharmacokinetic.
One of the important differences to make note of among the many SSRIs is actually their pharmacokinetic properties are linear or nonlinear.
Citalopram, escitalopram and sertraline show linear and dose-proportional pharmacokinetics. Plasma concentrations of such drugs are proportional to the daily dose administered and, therefore, predictable. In contrast, fluvoxamine, fluoxetine and paroxetine have nonlinear pharmacokinetics. Higher doses may produce much greater increases in plasma drug concentrations than would otherwise be expected. Thus, increasing the dose of paroxetine or fluoxetine can cause disproportionate and unpredictable increases in plasma levels, half-lives, and negative effects. Titration of fluoxetine and paroxetine doses may therefore be more difficult when compared to citalopram, escitalopram and sertraline.
Drug Interactions
The interaction between monoamine oxidase inhibitors (MAOIs) and SSRIs is a vital drug interaction limiting SSRI use. This combination may lead towards the development of a hyperserotonergic syndrome being made of excitement, diaphoresis, rigidity, hyperthermia, tachycardia, hypertension, and possibly death. The severity of this interaction necessitates at the very least 5 week washout when switching a private from fluoxetine to an MAOI to allow complete elimination of a typical fluoxetine. At least 14 days should really be allowed after stopping citalopram, escitalopram, paroxetine or sertraline before you begin an MAOI. This difference in washout time between fluoxetine and citalopram, escitalopram, paroxetine and sertraline when switching from an SSRI to an MAOI is one of the key differences between SSRIs.
Author Resource:-
Citalopram, escitalopram and sertraline side effects of Sertraline develop the lowest potential for drug interactions among the SSRIs. Citalopram should really be avoided in patients prone to take overdoses. Sertraline might possibly be Nexium side effectspreferable for cardiac patients taking beta blockers or type IC antiarrhythmic agents.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites